EligibleTrials

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Recruiting · NCT03817502 · Interventional (participants receive a specific treatment) · Lead sponsor: Gedeon Richter Plc.

View the official record on ClinicalTrials.gov →
Schizophrenia

Interventions studied

CariprazinePlacebo

What this trial is about

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Who can take part

Age range
13 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

57 locations listed across 7 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.